vimarsana.com
Home
Live Updates
Topline Results from Two-Year Primary Efficacy Endpoint in P
Topline Results from Two-Year Primary Efficacy Endpoint in P
Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
/PRNewswire/ -- CSL Vifor today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin...
Related Keywords
Switzerland ,
Australia ,
Melbourne ,
Victoria ,
Steve Pascoe ,
Vifor International ,
Fresenius Medical Care ,
Dual Endothelin Angiotensin Receptor Antagonist ,
Senior Vice President ,
Therapeutic Area Strategy ,
Efficacy Endpoints ,
Two Year Exploratory Endpoints ,
Travere Therapeutics ,
Vifor Fresenius Medical Care Renal Pharma ,
Vifor International Ag Csl ,